Xenon Pharmaceuticals (XENE) Misses Q2 EPS by 7c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Xenon Pharmaceuticals (XENE) Misses Q2 EPS by 7c

Xenon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

August 9, 2022 4:01 PM EDT

Xenon remains on track to initiate the XEN1101 Phase 3 program within second half of this year

Cash runway extended into 2026 following successful completion of equity offering in June

Conference Call at 4:30 pm ET Today

BURNABY, British Columbia, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neurology-focused biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2022 and provided a corporate update.

... More